# Scoping Review of the Biomedical Investigations of Cellulose Nanocrystal-Based Hydrogels: A Critical Analysis of Current Evidence, Research Gaps and Future Perspectives

**Authors:** Dinuki M. Seneviratne, Eliza J. Whiteside, Louisa C. E. Windus, Paulomi (Polly) Burey, Raelene Ward, Pratheep K. Annamalai

PMC · DOI: 10.3390/gels12030207 · 2026-02-28

## TL;DR

This review examines how cellulose nanocrystals improve hydrogels for biomedical uses, highlighting current research and areas needing standardization.

## Contribution

The paper uniquely focuses on biomedical models and assays for CNC-hydrogels, identifying methodological gaps and proposing standardization for translational success.

## Key findings

- CNC incorporation improved hydrogel mechanical properties by 20–40% and supported high cell viability for up to 21 days.
- In vivo studies showed benefits like preserved graft volume and reduced vascular hyperplasia, but lacked standardization and long-term data.
- Current research lacks human trials and consistent reporting, hindering reproducibility and translational progress.

## Abstract

Hydrogel-based products are used in many areas of biomedicine and healthcare. Recently, the incorporation of cellulose nanocrystals (CNC), a renewable and functional nanomaterial, into hydrogels has enhanced their functionality, particularly by imparting mechanical strength and structural integrity. This scoping review aims to appraise the types of biomedical models and assays that have been utilised to investigate the effects of CNC incorporation into hydrogels in tissue engineering, wound healing, medical implantation and drug delivery applications, and reports on the rationale for including these models and assays. A structured literature search was undertaken in major scientific databases (PubMed Central, PubMed, BioMed Central, ScienceDirect, Wiley and EBSCOhost), focusing on identifying primary research published between 2016 and 2024. From this process, fifteen studies providing biomedical analyses met the inclusion criteria. Most of these investigations employed in vitro cell-line models (n = 12), with a smaller number utilising in vivo experimental systems (n = 5). Across the included studies, CNC incorporation typically yielded measurable performance gains: reported compressive or storage modulus improvements of 20–40% over hydrogel-only controls, consistently high cell viability (>85%) across multiple human and murine cell types for up to 21 days, and sustained drug release profiles (days–weeks) in stent and antitumour contexts. Where quantified, functional outcomes in vivo included preserved graft volume (autologous fat grafts) and reduced intimal hyperplasia signals in vascular graft models. Critical gaps included heterogeneous CNC sources and surface chemistries, inconsistent reporting of CNC concentration and hydrogel formulation parameters, the limited duration and scope of biocompatibility testing, and minimal alignment with standard evaluation protocols, constraining reproducibility and cross-study comparability. To date, there are no human clinical trials of CNC-hydrogels. Translational readiness will require standardised ISO-compliant biocompatibility evaluations. Large-animal studies under relevant mechanical and physiological conditions, and rigorous long-term degradation and immunogenicity assessments to de-risk progression to human trials. We recommend standardised CNC sources and surface functionalisation reporting, concentration (wt%) ranges, hydrogel rheological characterisation (G′, G″, swelling), and consistent biological endpoints (viability, differentiation, inflammation panels) to enable robust meta-analyses and translational benchmarking. Distinct from prior nanocellulose reviews that emphasise material synthesis and properties, this analysis centres on the biomedical models and assays applied to CNC-incorporated hydrogels, identifying the methodological convergence and divergence that directly impact translational pathways.

## Linked entities

- **Species:** Homo sapiens (taxon 9606)

## Full-text entities

- **Genes:** PRKAR1A (protein kinase cAMP-dependent type I regulatory subunit alpha) [NCBI Gene 5573] {aka ACRDYS1, ADOHR, CAR, CNC, CNC1, PKR1}, Becn1 (beclin 1, autophagy related) [NCBI Gene 56208] {aka Atg6}, Nup62 (nucleoporin 62) [NCBI Gene 18226] {aka D7Ertd649e, Nupc1, p62}, Mtor (mechanistic target of rapamycin kinase) [NCBI Gene 56717] {aka 2610315D21Rik, FRAP, FRAP2, Frap1, RAFT1, RAPT1}, Mmp2 (matrix metallopeptidase 2) [NCBI Gene 17390] {aka Clg4a, GelA, MMP-2}, Twist1 (twist basic helix-loop-helix transcription factor 1) [NCBI Gene 22160] {aka M-Twist, Pde, Ska10, Ska<m10Jus>, Twist, bHLHa38}, Ptprc (protein tyrosine phosphatase receptor type C) [NCBI Gene 19264] {aka B220, CD45R, Cd45, L-CA, Ly-5, Lyt-4}, Pecam1 (platelet/endothelial cell adhesion molecule 1) [NCBI Gene 18613] {aka Cd31, PECAM-1, Pecam}, Il10 (interleukin 10) [NCBI Gene 16153] {aka CSIF, If2a, Il-10}, Nos2 (nitric oxide synthase 2, inducible) [NCBI Gene 18126] {aka MAC-NOS, NOS-II, Nos-2, Nos2a, i-NOS, iNOS}, Il4 (interleukin 4) [NCBI Gene 16189] {aka BSF-1, Il-4}, Cd68 (CD68 antigen) [NCBI Gene 12514] {aka Lamp4, Scard1, gp110}, Tgfb1 (transforming growth factor, beta 1) [NCBI Gene 21803] {aka TGF-beta1, TGFbeta1, Tgfb, Tgfb-1}, Acta2 (actin alpha 2, smooth muscle, aorta) [NCBI Gene 11475] {aka 0610041G09Rik, Actvs, SMAalpha, SMalphaA, a-SMA, alphaSMA}, Spp1 (secreted phosphoprotein 1) [NCBI Gene 20750] {aka 2AR, Apl-1, BNSP, BSPI, Bsp, ETA-1}, Adgre1 (adhesion G protein-coupled receptor E1) [NCBI Gene 13733] {aka DD7A5-7, EGF-TM7, Emr1, F4/80, Gpf480, Ly71}, Il3 (interleukin 3) [NCBI Gene 16187] {aka BPA, Csfmu, HCGF, Il-3, MCGF, PSF}, Sox9 (SRY (sex determining region Y)-box 9) [NCBI Gene 20682] {aka 2010306G03Rik, mKIAA4243, mSox9}, Il6 (interleukin 6) [NCBI Gene 16193] {aka Il-6}, Il13 (interleukin 13) [NCBI Gene 16163] {aka Il-13}, Mrc1 (mannose receptor, C type 1) [NCBI Gene 17533] {aka CD206, MR}, Itgam (integrin alpha M) [NCBI Gene 16409] {aka CD11b/CD18, CR3, CR3A, Cd11b, F730045J24Rik, Ly-40}, Acan (aggrecan) [NCBI Gene 11595] {aka Agc, Agc1, CSPCP, Cspg1, b2b183Clo, cmd}, Mmp13 (matrix metallopeptidase 13) [NCBI Gene 17386] {aka Clg, MMP-13, Mmp1}, ALPP (alkaline phosphatase, placental) [NCBI Gene 250] {aka ALP, PALP, PLAP, PLAP-1}, D9Mgc45e (DNA segment, Chr 9, MRC UK Mouse Genome Centre 45 expressed) [NCBI Gene 28134] {aka CD3}, Tnfsf10 (tumor necrosis factor (ligand) superfamily, member 10) [NCBI Gene 22035] {aka A330042I21Rik, APO-2L, Ly81, TL2, Tnlg6a, Trail}, Snai1 (snail family zinc finger 1) [NCBI Gene 20613] {aka Sna, Sna1, Snail, Snail1}, Snai2 (snail family zinc finger 2) [NCBI Gene 20583] {aka Slug, Slugh, Snail2}, Runx2 (runt related transcription factor 2) [NCBI Gene 12393] {aka AML3, CBF-alpha-1, Cbf, Cbfa-1, Cbfa1, LS3}, Il1b (interleukin 1 beta) [NCBI Gene 16176] {aka IL-1beta, Il-1b}, Vim (vimentin) [NCBI Gene 22352], alp (alopecia, recessive) [NCBI Gene 11691], Bglap2 (bone gamma-carboxyglutamate protein 2) [NCBI Gene 12097] {aka BGP2, Bglap1, Bgp, Og2, mOC-B}, Dntt (deoxynucleotidyltransferase, terminal) [NCBI Gene 21673] {aka Tdt}, Il2 (interleukin 2) [NCBI Gene 16183] {aka Il-2}
- **Diseases:** calcification (MESH:D002114), inflammation (MESH:D007249), intimal hyperplasia (MESH:D006965), swelling (MESH:D004487), EndMT (MESH:D008579), tumour (MESH:D009369), Restenosis (MESH:D023903), glioblastoma multiforme tumour (MESH:D005909), valve calcification (MESH:C562942), cervical cancer (MESH:D002583), cytotoxicity (MESH:D064420), injury to (MESH:D014947)
- **Chemicals:** haematoxylin (MESH:D006416), DMMB (MESH:C435946), sulphur (MESH:D013455), Cellulose (MESH:D002482), alginate (MESH:D000464), ethidium homodimer (MESH:C018533), MTT (MESH:C070243), Alizarin (MESH:C010078), water (MESH:D014867), DCFH-DA (MESH:C029569), hydroxyl (MESH:D017665), ROS (MESH:D017382), Alcian blue (MESH:D000423), 2-hydroxy-2-methylpropiophenone (MESH:C492094), H&amp;E (MESH:D006371), calcein AM (MESH:C085925), chitosan (MESH:D048271), propidium iodide (MESH:D011419), eosin (MESH:D004801), resazurin (MESH:C005843), BIS (MESH:D001729), doxorubicin (MESH:D004317), agar (MESH:D000362), polymer (MESH:D011108), sulphate (MESH:D013431), AS-IV (-), ethidium (MESH:D004996), riboflavin (MESH:D012256), CBC (MESH:C010695), CNCs (MESH:D000069449), hydrogen (MESH:D006859), calcium (MESH:D002118), hydroxyproline (MESH:D006909), astragaloside-IV (MESH:C052064), apatite (MESH:D001031), dUTP (MESH:C027078)
- **Species:** Escherichia coli (E. coli, species) [taxon 562], Rattus norvegicus (brown rat, species) [taxon 10116], Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090], Staphylococcus aureus (species) [taxon 1280], Cercopithecidae (monkey, family) [taxon 9527]
- **Cell lines:** L929 — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_AR58), TC28a2 — Homo sapiens (Human), Transformed cell line (CVCL_6850), H22 — Homo sapiens (Human), Peripheral primitive neuroectodermal tumor of bone, Cancer cell line (CVCL_1E32), CCK8 — Homo sapiens (Human), Colon adenocarcinoma, Cancer cell line (CVCL_2873), ATDC5 — Mus musculus (Mouse), Mouse teratocarcinoma, Cancer cell line (CVCL_3894), Balb/C — Mus musculus (Mouse), Mouse thymic lymphoma, Cancer cell line (CVCL_C5SS), B16F10 — Mus musculus (Mouse), Mouse melanoma, Cancer cell line (CVCL_0159), NIH-3T3 — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_0594), COS-7 — Chlorocebus aethiops (Green monkey), Transformed cell line (CVCL_0224), HeLa — Homo sapiens (Human), Human papillomavirus-related endocervical adenocarcinoma, Cancer cell line (CVCL_0030), MC3T3-E1 — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_0409)

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13025112/full.md

---
Source: https://tomesphere.com/paper/PMC13025112